Skip to main content

Advertisement

Table 3 Numerical results of sub-site

From: Correlation between egfr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma

 Sub-site Number of patients Doubling time Flow Cytometric (FCM) Immunohistochemical (Hi)
days Dp(0.25) Dp(0.3) Dp(0.35) days Dp(0.25) Dp(0.3) Dp (0.35)
Oral Cavity 394 (18.2%) T D 6.6 (5.5-8.2) 0.35 (0.28-0.42) 0.29 (0.23-0.35) 0.25 (0.20-0.30) 5.9 (4.9-7.4) 0.39 (0.31-0.47) 0.33 (0.26-0.39) 0.28 (0.22-0.34)
T pot 3.9 0.59 0.49 0.42 2.3 1.00 0.84 0.72
Oropharynx 655 (30.3%) T D 6.6 (5.5-8.2) 0.35 (0.28-0.42) 0.29 (0.23-0.35) 0.25 (0.20-0.30) 5.9 (4.9-7.4) 0.39 (0.31-0.47) 0.33 (0.26-0.39) 0.28 (0.22-0.34)
T pot 3.9 0.59 0.49 0.42 2.3 1.00 0.84 0.72
Hypopharynx 320 (14.8%) T D 6.1 (5.1-7.6) 0.38 (0.30-0.45) 0.31 (0.25-0.38) 0.27 (0.22-0.32) 4.6 (3.9-5.8) 0.50 (0.40-0.59) 0.42 (0.33-0.49) 0.36 (0.28-0.42)
T pot 3.6 0.64 0.53 0.46 1.8 1.28 1.07 0.92
Larynx 784 (36.3%) T D 12.9 (10.7-16.0) 0.18 (0.14-0.22) 0.15 (0.12-0.18) 0.13 (0.10-0.15) 14.3 (12.4-18.1) 0.16 (0.13-0.19) 0.14 (0.11-0.16) 0.12 (0.9-0.13)
T pot 7.6 0.30 0.25 0.46 5.6 0.41 0.34 0.29
  1. T D (days) and D prolif (Gy/day) for high EGFr expression group (<iT pot > =5.2 days by flow cytometry; <iT pot > =3.4 days by immunohistochemistry; T K  = 21 days). The iT D for each i sub-site (upper rows) is almost twice of iT pot by flow cytometry and more than double of iT pot by immunohistochemistry from literature (bottom rows) [15]. Consequently, a preclinical estimation of D prolif by flow cytometry (left columns, bottom rows) or immunohistochemistry (right columns, bottom rows), results almost double and more than double if compared to the estimation of D prolif obtained by mathematical model (left and right columns, upper rows), respectively. The 95 % confidence intervals are shown within the brackets.
  2. Abbreviations: iDp(0.25; 0.3; 0.35) = D prolif calculated with α = 0.25, α = 0.3, α = 0.35 Gy-1 respectively, α/β = 10 Gy, d = 2 Gy.